Properties
What is it?
International Nonproprietary Name - Meropenum Pharmacological group: Carbapenem group Chemical name: (-)-(4R,5S,6S)-3-[[(3S,5S)-5-(dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid trihydrate Active ingredients: Meropenem trihydrate 570 mg; 1140 mg Equivalent meropenem anhydrous 500 mg; 1000 mg Excipients: Sodium carbonate anhydrous 104 mg; 208 mg Indications for use Meropenem for intravenous administration is used in children and adults to treat infections caused by one or more pathogens susceptible to meropenem: - Pneumonias, including hospital-acquired pneumonia - Urinary tract infections - Intra-abdominal infections - Gynecological infections, such as endometritis and pelvic inflammatory disease - Skin and soft tissue infections - Meningitis - Septicemia - Empirical treatment as monotherapy or in combination with antiviral or antifungal agents in adult patients with suspected infection in the presence of febrile neutropenia. Meronem has shown efficacy as monotherapy or in combination with other antimicrobial agents in the treatment of polymicrobial infections. There is no experience with the use of the drug in pediatric practice in patients with neutropenia or primary or secondary immunodeficiency. Dosage and administration Adults Dosage and duration of treatment should be determined by the type and severity of infection and the patient's condition. The following daily doses are recommended: 500 mg intravenously every 8 hours for the treatment of pneumonia, urinary tract infections, gynecological infections such as endometritis, skin and skin structure infections. 1 g intravenously every 8 hours for the treatment of hospital-acquired pneumonia, peritonitis in patients with symptoms of neutropenia, suspected bacterial infection, and also septicemia. For the treatment of meningitis, the recommended dose is 2 g every 8 hours. For children from 3 months to 12 years, the recommended dose for intravenous administration is 10-20 mg/kg every 8 hours, depending on the type and severity of infection, the susceptibility of the pathogenic microorganism, and the patient's condition. In children weighing more than 50 kg, the adult dose should be used. In case of meningitis, the recommended dose is 40 mg/kg every 8 hours. There is no experience with the use of the drug in children with impaired renal function. Administration Meronem for intravenous use can be administered as a bolus injection over at least 5 minutes, or as an intravenous infusion over 15-30 minutes, using an appropriate infusion fluid for dilution. Meronem for intravenous bolus injection should be diluted with sterile water for injection (5 ml per 250 mg meropenem), with a solution concentration of approximately 50 mg/ml. The resulting solution is a clear, colorless or pale yellow liquid. Meronem for intravenous infusion can be diluted with a compatible infusion fluid (50 to 200 ml). Meronem should not be mixed or added to other drugs. Side effects Serious adverse reactions are rare. The following adverse reactions are mainly observed: Local reactions: inflammation, phlebitis, pain at the injection site. Systemic allergic reactions: In rare cases, systemic allergic reactions (hypersensitivity) may occur after administration of Meronem. These reactions can manifest as angioneurotic edema and anaphylaxis. Skin reactions: rash, itching, urticaria. In rare cases, serious skin reactions such as erythema multiforme (exudative), Stevens-Johnson syndrome, and toxic epidermal necrolysis are observed. Gastrointestinal: abdominal pain, nausea, vomiting, diarrhea. Cases of pseudomembranous colitis have also been reported.